Overview
Charles River
Founded in 1947 and went public in 2000, Charles River Laboratories International is a full service, leading, non-clinical global drug development partner to pharmaceutical firms and other manufacturers and institutions. It provides contract drug discovery services, including target identification and toxicology, through its Discovery and Safety Assessment (DRS) segment. Its Research Models and Services (RMS) segment is a leading global provider of
...
Read More research models (lab rats and mice) bred specifically for use in medical testing. The Manufacturing Support segment offers biologics testing and chicken eggs for vaccines. Charles River has operations in over 20 countries, but generates more than 55% of revenue in the US.
Read Less
Read More research models (lab rats and mice) bred specifically for use in medical testing. The Manufacturing Support segment offers biologics testing and chicken eggs for vaccines. Charles River has operations in over 20 countries, but generates more than 55% of revenue in the US.
Read Less
#
769
Fortune 1000 Revenue Rank
James C Foster
See more contacts
Scientific Research and Development Services
,
Architectural, Engineering, and Related Services
,
Professional, Scientific, and Technical Services
,
Commercial physical research
,
Testing laboratories
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Modelled
?
Actual
$4.05 billion
Actual
-1.92%
-97.83%
$7,528
DEC
?
?
NYSE:CRL
Contacts
Get in Touch with 5 Principals* and 417 Contacts
-
James C FosterChairman of the Board and President and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 28, 2024 (12 month period) in USD
Annual Revenue 2024
$4.05 billion
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $735 | $684 | $620 |
| Net Investing Cash | -$245 | -$563 | -$608 |
| Net Financing Cash | -$551 | -$86 | -$42 |
| Net Change in Cash | -$61 | $35 | -$31 |
| Cash at Beginning of Period | $284 | $241 | $246 |
| Cash at End of Period | $206 | $284 | $241 |
| Capital Expenditure | -$233 | -$319 | -$325 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $195 | $277 | $234 |
| Accounts Receivable | $528 | $578 | $559 |
| Inventories | $279 | $380 | $256 |
| Other Current Assets | $402 | $374 | $390 |
| Asset Summary | |||
| Total Current Assets | $1,403 | $1,609 | $1,439 |
| Tangible Fixed Assets | $2,017 | $2,034 | $1,857 |
| Intangible Assets | $723 | $864 | $955 |
| Total Assets | $7,528 | $8,195 | $7,603 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $140 | $169 | $206 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $854 | $886 | $886 |
| Liability Summary | |||
| Total Current Liabilities | $994 | $1,055 | $1,092 |
| Long-Term Debt | $2,240 | $2,647 | $2,708 |
| Other Long-Term Liabilities | $195 | $223 | $175 |
| Total Liabilities | $4,020 | $4,536 | $4,579 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $1 | $1 | $1 |
| Retained Earnings | $1,812 | $1,887 | $1,433 |
| Equity Summary | |||
| Total Equity | $3,462 | $3,597 | $2,976 |
| Shares Outstanding | 51,141,000 | 51,338,000 | 50,944,000 |